This company listing is no longer active
PBP Stock Overview
Engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Probiotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.98 |
| 52 Week High | AU$3.03 |
| 52 Week Low | AU$2.14 |
| Beta | 0.47 |
| 11 Month Change | 2.05% |
| 3 Month Change | 6.81% |
| 1 Year Change | 11.61% |
| 33 Year Change | 39.91% |
| 5 Year Change | 91.03% |
| Change since IPO | 158.01% |
Recent News & Updates
Shareholder Returns
| PBP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -16.3% | 0.9% |
| 1Y | 11.6% | 35.0% | 17.7% |
Return vs Industry: PBP underperformed the Australian Pharmaceuticals industry which returned 63.2% over the past year.
Return vs Market: PBP exceeded the Australian Market which returned 6.1% over the past year.
Price Volatility
| PBP volatility | |
|---|---|
| PBP Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: PBP has not had significant price volatility in the past 3 months.
Volatility Over Time: PBP's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Wes Stringer | www.probiotec.com.au |
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.
Probiotec Limited Fundamentals Summary
| PBP fundamental statistics | |
|---|---|
| Market cap | AU$242.34m |
| Earnings (TTM) | AU$8.69m |
| Revenue (TTM) | AU$221.22m |
27.9x
P/E Ratio1.1x
P/S RatioIs PBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBP income statement (TTM) | |
|---|---|
| Revenue | AU$221.22m |
| Cost of Revenue | AU$154.96m |
| Gross Profit | AU$66.25m |
| Other Expenses | AU$57.57m |
| Earnings | AU$8.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 29.95% |
| Net Profit Margin | 3.93% |
| Debt/Equity Ratio | 52.5% |
How did PBP perform over the long term?
See historical performance and comparison